[4] – Schneeberger Daniel (CIK 0001861120)
Rhea-AI Filing Summary
Keros Therapeutics (KROS): Section 16 filing reports insider sales. On 10/15/2025, reporting persons linked to ADAR1 disclosed sales of Keros common stock at $17.75 per share. The transactions were reported as indirect holdings through affiliated entities.
Reported sales included 4,391,237 shares by ADAR1 Partners, LP; 254,669 shares by ADAR1 SPV I, LP; and 743,358 shares by Spearhead Insurance Solutions IDF, LLC. For each line item, the amount of securities beneficially owned following the transactions was listed as 0, with ownership form marked as indirect.
The filing notes that ADAR1 Capital Management, LLC (investment manager/sub‑advisor), ADAR1 Capital Management GP, LLC (general partner), and Daniel Schneeberger (manager) may be deemed to indirectly beneficially own the securities, and each disclaims beneficial ownership except to the extent of pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Form 4 shows indirect sales at $17.75; post-transaction lines show 0 held.
This Section 16 report lists sales of Keros common stock on 10/15/2025 at $17.75 per share by entities associated with ADAR1. The amounts are reported by holder: ADAR1 Partners, LP 4,391,237; ADAR1 SPV I, LP 254,669; Spearhead Insurance Solutions IDF, LLC 743,358, each shown as indirectly held.
For each entry, the amount of securities beneficially owned following the transactions is stated as 0, indicating no remaining reported holdings for those line items. The filing includes standard Section 16 disclaimers that the reporting persons may be deemed to beneficially own the securities through management and partnership roles, while disclaiming beneficial ownership except to pecuniary interest.
Actual market impact depends on transaction execution details and broader trading activity; the filing documents the reported sales and indirect ownership structure.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 4,391,237 | $17.75 | $77.94M |
| Sale | Common Stock | 254,669 | $17.75 | $4.52M |
| Sale | Common Stock | 743,358 | $17.75 | $13.19M |
Footnotes (1)
- The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.